Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
APO-DIMETHYL FUMARATE, DIMETHINTAS, DIMETHYL FUMARATE ASTRON, DIMETHYL FUMARATE INTAS, TECFUMARA, TECINTAS (Accord Healthcare Pty Ltd)
Product name
APO-DIMETHYL FUMARATE, DIMETHINTAS, DIMETHYL FUMARATE ASTRON, DIMETHYL FUMARATE INTAS, TECFUMARA, TECINTAS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days)
Active ingredients
Dimethyl fumarate
Registration type
New generic medicine
Indication
APO-DIMETHYL FUMARATE, DIMETHINTAS, DIMETHYL FUMARATE ASTRON, DIMETHYL FUMARATE INTAS, TECFUMARA, TECINTAS (enteric coated capsule) is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.